Quinuclidine derivatives and pharmaceutical compositions...

Details Quinuclidine derivatives and pharmaceutical compositions... Quinuclidine derivatives and pharmaceutical compositions...

2003-06-18

2008-10-14

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S305000, C546S137000, C546S183000

Reexamination Certificate

active

07435742

ABSTRACT:
Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

REFERENCES:
patent: 2762796 (1956-09-01), Morel et al.
patent: 3714357 (1973-01-01), Gueremy et al.
patent: 6916828 (2005-07-01), Farrerons Gallemi et al.
patent: 7208501 (2007-04-01), Buil Albero et al.
patent: 7312231 (2007-12-01), Buil Albero et al.
patent: 2004/0063950 (2004-04-01), Farrerons Gallemi et al.
patent: 2004/0235887 (2004-11-01), Farrerons Gallemi et al.
patent: 2004/0242629 (2004-12-01), Buil Albero et al.
patent: 2004/0266816 (2004-12-01), Buil Albero et al.
patent: 2005/0043349 (2005-02-01), Catena Ruiz et al.
patent: 2008/0021060 (2008-01-01), Buil Albero et al.
patent: 2155320 (1993-08-01), None
patent: 0 424 021 (1991-04-01), None
patent: 0 747 355 (1996-12-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 2 012 964 (1970-03-01), None
patent: 1 246 606 (2005-07-01), None
patent: 09-328469 (1997-12-01), None
patent: WO 93/15080 (1993-08-01), None
patent: WO01/04118 (2001-01-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO02/00652 (2002-01-01), None
patent: 02/00652 (2002-03-01), None
patent: 02/051841 (2002-07-01), None
patent: WO02/051841 (2002-07-01), None
patent: WO02/053564 (2002-07-01), None
patent: 03/053966 (2003-07-01), None
patent: WO 03/053966 (2003-07-01), None
patent: WO 2004/000840 (2003-12-01), None
patent: WO 2004/005285 (2004-01-01), None
Profita et al., Allergy, 2005, vol. 60, pp. 1361-1369.
N.N. Godovikov, et al., “Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides”, Khim. Farm. Zh., vol. 19, No. 9, pp. 1060-1061, 1985.
J. Lars et al., “Some quinuclidine derivatives with potential antimalarial activity”,Acta Pharm. Suecica, vol. 5, pp. 71-76, 1968.
L. Noronha-Blob et al., “Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate”,European Journal of Pharmacology, vol. 221, pp. 97-103, 1992.
S.H. Gao et al., “Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit”,Chemical Journal of Chinese Universities, vol. 20, No. 2, pp. 232-236, 1999.
PCT International Search Report dated Dec. 5, 2003.
Abstract for Wallis, R.M. & Napier, C.M. Life Sci. 64(6-7):395-401 (1996) PMID 10069502.
Abstract for White, M.V. J. Allergy Clin. Immunol. 95(5 pt 2): 1065-68 (1995) PMID 7751523.
Brown, J.H. and Taylor, P. (2001) “Muscarinic Receptor Agonists and Antagonists,” Chapter 7 in The Pharmacological Basis of Therapies. Goodmen et al. eds., McGraw Hill: 10th edition, pp. 155-173.
Eglen, R.M. and Hedge, S.S. (1997) “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential,” Drug News Perspect. 10(8): 462-469.
Eglen, R.M. et al. “Therapeutic opportunities from muscarinic receptor research,” Trends in Pharm. Sci. 22(8), Aug. 2001, 409-414.
Fryer et al., Am. J. Respir. Crit. Care Med. 158:S154-S160 (1998).
Interview Summary dated Jan. 19, 2006, from U.S. Appl. No. 10/404,395.
Interview Summary/Office Action dated Feb. 28, 2005, from U.S. Appl. No. 10/404,395.
Interview Summary/Office Action dated Feb. 28, 2005, in U.S. Appl. No. 10/193,622.
Konzett, H. and Rossler, R. (1940). “Versuchsanordnung zu Untersuchungen an der Brochialmuskulatur,” Arch. Exp. Path. Pharmacol. 195: 71-74.
Notice of Allowance/Notice of Allowability, dated Jan. 19, 2006, from U.S. Appl. No. 10/404,395.
Office Action dated Feb. 3, 2005, from U.S. Appl. No. 10/404,395.
Office Action dated Feb. 3, 2005, in U.S. Appl. No. 10/193,622.
Office Action dated May 18, 2005, from U.S. Appl. No. 10/404,395.
Office Action dated May 18, 2005, in U.S. Appl. No. 10/193,622.
Office Action dated Nov. 1, 2005, in U.S. Appl. No. 10/193,622.
Rang, H.P. et al. (1995). “Cholinergic Transmission,” Chapter 6 in Pharmacology. Churchill Livingstone, New York, NY. 3rd Edition, pp. 117-147.
Ringdahl, R. et al. (1979). “Facile Preparation of the Enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol,” Acta Pharm Suec. 16: 281-283.
Saraswati, M. et al. (1994). “Structure Activity Studies of N,N-Dialkyl and Cycloalkyl Carbamate Esters of Dimethylethanolamine and Choline with Nicotine and Muscarinic Cholinergic Properties,” Drug Development Research 31: 142-146.
Shutske, G.M. (1990) “A Novel Synthesis of the Isoxazolo[5,4,3-kl]-acridine Ring System,” J. Heterocyclic Chem. 27: 1617-1621.
van Zwieten et al. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 1995, 9(1): 159-67.
Waelbroeck, M. et al. (1990). “Binding of Selective Antagonists to Four Muscarinic Receptors (M1 to M4) in Rat Forebrain,” Molecular Pharmacology. 38:267-273.
Xu et al. Chemical & Pharmaceutical Bulletin, 1998, 46(2): 231-241.
Notice of Allowance/Notice of Allowability, dated May 25, 2006, from U.S. Appl. No. 10/193,622.
Office Action dated Jul. 13, 2006, from U.S. Appl. No. 10/404,395.
Interview Summary, dated Jun. 13, 2006, from U.S. Appl. No. 10/193,622.
Notice of Allowance/Notice of Allowability, dated Jul. 27, 2006, from U.S. Appl. No. 10/193,622.
Office Action dated Nov. 8, 2006, from U.S. Appl. No. 10/404,395.
Notice of Allowance/Notice of Allowability, dated Mar. 26, 2007, from U.S. Appl. No. 10/404,395.

Affiliated with

Also associated with

Rating

Quinuclidine derivatives and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinuclidine derivatives and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinuclidine derivatives and pharmaceutical compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4018307